[Regulation of skeletal muscle mass and adipose tissue mass by follistatin and follistatin-related gene (FLRG) and development of novel polypeptides as medical drugs].
Tsuchita
Kunihiro
K
Division for Therapies Against Intractable Diseases, Institute for Comprehensive Medical Sciences, Fujita Health University, Kutsukate-cho, Toyoake, Japan.
D030301:Activin Receptors, Type II / Q000502:physiology; D028341:Activins / Q000502:physiology; D000273:Adipose Tissue / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D015195:Drug Design; D038681:Follistatin / Q000494:pharmacology / Q000502:physiology*; D038702:Follistatin-Related Proteins / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D018482:Muscle, Skeletal / Q000378:metabolism* / Q000473:pathology; D055435:Myostatin; D010455:Peptides; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000502:physiology
D038681:Follistatin; D038702:Follistatin-Related Proteins; C525911:MSTN protein, human; D055435:Myostatin; D010455:Peptides; D016212:Transforming Growth Factor beta; D028341:Activins; D030301:Activin Receptors, Type II; C425585:activin receptor type II-A; C425584:activin receptor type II-B